Dec 3 (Reuters) - Hong Kong stocks ended marginally higher
on Thursday, lifted by hopes for additional U.S. economic
stimulus and optimism over a COVID-19 vaccine that could
potentially bring the pandemic under control.
** Britain approved Pfizer Inc's COVID-19 vaccine on
Wednesday, jumping ahead of the rest of the world in the race to
begin the most crucial mass inoculation programme in history.
** Meanwhile, the Institute of Microbiology at the Chinese
Academy of Sciences said on Thursday that it worked with China's
Chongqing Zhifei to carry out phase III trial of a
coronavirus vaccine in Hunan province in November.
** At the close of trade, the Hang Seng index was up
195.92 points or 0.74% at 26,728.50. The Hang Seng China
Enterprises index rose 0.12% to 10,586.37.
** The top gainer in the Hang Seng was CSPC Pharmaceutical Group
Ltd, which gained 5.91%, while the biggest loser was
CITIC Ltd, which fell 6.47%.
** Some investors said the market also looked forward to
additional economic stimulus from Washington. Republicans and
Democrats in Congress remained unable to reach agreement on
fresh relief for a pandemic-hit U.S. economy on Wednesday,
however, there were early signs that a $908 billion bipartisan
proposal could be gaining traction as a negotiating tool.
** Around the region, MSCI's Asia ex-Japan stock index
was firmer by 0.27%, while Japan's Nikkei index
closed up 0.03%.
(Reporting by Winni Zhou and Andrew Galbraith, Editing by